WO2002055661A3 - Fatty acid synthase inhibitors - Google Patents
Fatty acid synthase inhibitors Download PDFInfo
- Publication number
- WO2002055661A3 WO2002055661A3 PCT/US2001/051330 US0151330W WO02055661A3 WO 2002055661 A3 WO2002055661 A3 WO 2002055661A3 US 0151330 W US0151330 W US 0151330W WO 02055661 A3 WO02055661 A3 WO 02055661A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- acid synthase
- synthase inhibitors
- inhibitors
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
This invention relates to the novel use of urea beta-lactam compounds as inhibitors of the fatty acid synthase FabH.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002243439A AU2002243439A1 (en) | 2000-11-17 | 2001-11-16 | Fatty acid synthase inhibitors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24964700P | 2000-11-17 | 2000-11-17 | |
| US60/249,647 | 2000-11-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002055661A2 WO2002055661A2 (en) | 2002-07-18 |
| WO2002055661A3 true WO2002055661A3 (en) | 2003-02-13 |
Family
ID=22944400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/051330 Ceased WO2002055661A2 (en) | 2000-11-17 | 2001-11-16 | Fatty acid synthase inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002243439A1 (en) |
| WO (1) | WO2002055661A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075077A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| WO2012037298A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| KR102194745B1 (en) | 2013-03-13 | 2020-12-24 | 포르마 세라퓨틱스 인크. | Novel compounds and compositions for inhibition of fasn |
| CN109890804A (en) | 2016-05-30 | 2019-06-14 | 慕尼黑工业大学 | Compounds containing urea moieties and their derivatives as antibacterial drugs |
| TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
| EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOLE-5-YL)BENZOYL)PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
-
2001
- 2001-11-16 AU AU2002243439A patent/AU2002243439A1/en not_active Abandoned
- 2001-11-16 WO PCT/US2001/051330 patent/WO2002055661A2/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| CHEMICAL COMMUNICATIONS, vol. 15, 1999, pages 1383 - 1384 * |
| DATABASE HCAPLUS [online] TANAKA ET AL.: "Thiazolium-dependent catalytic antibodies produced using a covalent modification strategy", XP002956148, accession no. STN Database accession no. 1999:447121 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002055661A2 (en) | 2002-07-18 |
| AU2002243439A1 (en) | 2002-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002238418A1 (en) | Use of DNA repair enzymes as MMP-1 inhibitors | |
| MXPA03000772A (en) | Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase. | |
| AU2001236720A1 (en) | Compositions useful as inhibitors of erk | |
| HK1044481A1 (en) | Indole compounds | |
| ZA200304893B (en) | Ether derivatives useful as inhibitors of PDE4 isozymes. | |
| WO2003074500A3 (en) | N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors | |
| WO2001087882A3 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
| NO20014837D0 (en) | Pyrazole compositions useful as inhibitors of ERK | |
| AU2001245764A1 (en) | Novel compounds and compositions as protease inhibitors | |
| AU2001270200A1 (en) | Fatty acid synthase inhibitors | |
| AU2002358067A1 (en) | Nitrogen-containing compounds as corrosion inhibitors | |
| HK1047927A1 (en) | Fatty acid synthase inhibitors | |
| AU2001296515A1 (en) | Cyclic sulfonyl compounds as inhibitors of metalloproteases | |
| AU2001281059A1 (en) | Fatty acid synthase inhibitors | |
| ZA200306327B (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid. | |
| WO2002055661A3 (en) | Fatty acid synthase inhibitors | |
| EP1435932A4 (en) | Inhibitors of rnase p proteins as antibacterial compounds | |
| HK1047928A1 (en) | Fatty acid synthase inhibitors | |
| WO2003059323A3 (en) | Stable salts of o-acetylsalicylic acid containing basic amino acids ii | |
| AU2001271531A1 (en) | Fatty acid synthase inhibitors | |
| IL161476A0 (en) | Phosphonic acid compounds as inhibitors of serine proteases | |
| WO2002009651A3 (en) | Fatty acid synthase inhibitors | |
| AU2001274940A1 (en) | Fatty acid synthase inhibitors | |
| AU2001225373A1 (en) | Urea compounds as inhibitors for vla-4 | |
| HK1044482A1 (en) | Indole compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |